Division for Planning, Monitoring, and Economics, National Cancer Center, 13370 Ulaanbaatar, Mongolia.
Division for Cancer Registry and Screening, National Cancer Center, 13370 Ulaanbaatar, Mongolia.
J Integr Neurosci. 2022 Jan 28;21(1):24. doi: 10.31083/j.jin2101024.
No epidemiological study on central nervous system tumours is available for Mongolia. The aim of this study was to determine the incidence, mortality and survival of people diagnosed with central nervous system tumours in Mongolia. It reports cancer data for the entire population (3.3 million) during the period between 2015 and 2019. Data was obtained from the National Cancer Registry of Mongolia. Diagnosis of tumours was established according to the diagnostic criteria of the International Classification of Diseases-10 (ICD-10). Incidence and mortality rates were calculated as mean annual numbers per 100,000 population. Age-standardized incidence and age-standardized mortality rates were calculated from age-specific rates by weighting directly from the World Standard Population. The three-year survival from 2015 through 2017 was calculated between treatment types by the Kaplan-Meier survival analysis. It found 515 (adults: 83 %; children: 17%) newly diagnosed central nervous system tumour cases over the five year period. The national age-standardized incidence of central nervous system tumours for the entire population was 3.7 per 100,000. The rate was higher for males than females (4.2 versus 3.4 per 100,000, respectively). Only 23% of the diagnosed cases were confirmed histologically. The most common tumour was glioma (57.6% of histologically verified tumours). In children (age 0-19 years) the age-specified incidence rate of tumours was 1.4 per 100,000. Geographically, the age-standardized incidences of the Eastern region were higher than the country average rates for both genders. During the period, 381 deaths were registered with an age-standardized mortality rate of 3.0 per 100,000 population. Furthermore, the overall three-year survival rate was 40.6% (out of 283 patients, 115 survived). The five-year prevalence of tumours was 183 and the mean per 100,000 population was 5.5. In conclusion, the data from the National Cancer Registry indicate that the incidence and survival rates of central nervous system tumours in Mongolia are relatively low. The most common location of central nervous system tumours was the brain. Glioma was the most common tumour among histologically confirmed cases. Despite the limitations, data from this study should provide information for national health policy and health care assessment. To improve the diagnosis, prognosis and treatment of central nervous system tumours, expansion of the cancer registry through collecting data on non-malignant tumours, increasing the rate of histological verification, conducting studies on cancer epidemiology and the introduction of advanced treatment technologies for central nervous system tumours are recommended.
蒙古尚无中枢神经系统肿瘤的流行病学研究。本研究旨在确定蒙古中枢神经系统肿瘤患者的发病率、死亡率和生存率。该研究报告了 2015 年至 2019 年期间整个人口(330 万)的癌症数据。数据来自蒙古国家癌症登记处。肿瘤的诊断根据国际疾病分类第十版(ICD-10)的诊断标准确定。发病率和死亡率按每 10 万人中每年的平均数计算。年龄标准化发病率和死亡率通过直接对世界标准人口进行加权,从年龄特异性比率计算得出。通过 Kaplan-Meier 生存分析,在 2015 年至 2017 年期间,根据治疗类型计算了 3 年生存率。在五年期间,发现 515 例(成人:83%;儿童:17%)新诊断的中枢神经系统肿瘤病例。全人群中枢神经系统肿瘤的全国年龄标准化发病率为每 10 万人 3.7 例。男性发病率高于女性(分别为每 10 万人 4.2 例和 3.4 例)。只有 23%的确诊病例经组织学证实。最常见的肿瘤是神经胶质瘤(57.6%的组织学确诊肿瘤)。在儿童(0-19 岁)中,肿瘤的年龄特异性发病率为每 10 万人 1.4 例。在地理上,东部地区的年龄标准化发病率高于男女两性的全国平均水平。在此期间,有 381 人死亡,标准化死亡率为每 10 万人 3.0 人。此外,总体三年生存率为 40.6%(283 例患者中有 115 例存活)。肿瘤五年患病率为 183 例,平均每 10 万人 5.5 例。总之,国家癌症登记处的数据表明,蒙古中枢神经系统肿瘤的发病率和生存率相对较低。中枢神经系统肿瘤最常见的部位是大脑。神经胶质瘤是组织学确诊病例中最常见的肿瘤。尽管存在局限性,但本研究的数据应为国家卫生政策和医疗保健评估提供信息。为了改善中枢神经系统肿瘤的诊断、预后和治疗,建议通过收集非恶性肿瘤数据扩大癌症登记处、提高组织学验证率、开展癌症流行病学研究以及引进中枢神经系统肿瘤先进治疗技术。